A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population
NCT ID: NCT00930722
Last Updated: 2011-05-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
329 participants
OBSERVATIONAL
2009-06-30
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients
NCT00313547
Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension
NCT04559074
Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
NCT03640312
Low-dose Quadruple Combination Therapy in Patients With Hypertension
NCT05377203
Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
NCT02940548
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
quinapril
quinapril
quinapril
per label as non interventional study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
quinapril
per label as non interventional study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Women of child bearing age, not willing to use contraceptives, will not be eligible for the study
* Women using oral contraceptives will also not be included in the study
* Patients who have received any drug other than Acupil® as the first prescribed antihypertensive would not be eligible for enrollment into the trial
* Patients having any complication at Week 0 visit which would require more thorough investigations or who required more than one anti-hypertensive drug at the time of initiation of their therapy will not be included in the study
* Patients having any contraindications as per the LPD of Acupil®
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Patna, Bihar, India
Pfizer Investigational Site
Ahmedabad, Gujarat, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Ahmedabad, Maharashtra, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Nagpur, Maharashtra, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Delhi, New Delhi, India
Pfizer Investigational Site
Jaipur, Rajasthan, India
Pfizer Investigational Site
Chennai, Tamil Nadu, India
Pfizer Investigational Site
Madurai, Tamil Nadu, India
Pfizer Investigational Site
Madurai, Tamil Nadu, India
Pfizer Investigational Site
Madurai, Tamil Nadu, India
Pfizer Investigational Site
Madurai, Tamil Nadu, India
Pfizer Investigational Site
Trichy, Tamil Nadu, India
Pfizer Investigational Site
Kanpur, Uttar Pradesh, India
Pfizer Investigational Site
Kolkata, West Bengal, India
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A9061066
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.